Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
Date:8/1/2011

f Arena's most advanced drug candidate and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looki
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
2. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
3. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
4. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
5. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
6. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
7. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
9. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
10. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Highest Rate of TB Infection in U.S., SAN ... of tuberculosis (TB) in the U.S., with recurrent outbreaks ... recent study on,homelessness and TB by Harvard Medical School. ... San Francisco. To address this health care,crisis, St. Anthony,s ...
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... of the National Institutes of Health,has started ... for patients with,metastatic melanoma using systemic administration ... reovirus. The trial is,being carried out by ...
Cached Medicine Technology:National Healthcare for Homeless Day: August 13th, 2008 2U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R) 2
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... -- Researchers from The Miriam Hospital have ... (COPD) who are also depressed have difficulty sticking ... be particularly true for women, and screening and ... part of treatment. The study and its findings ... . , Chronic obstructive pulmonary disease is ...
(Date:7/9/2014)... KNOXVILLEAmphibian declines and extinctions around the world have ... chytridiomycosis, but new research from the National Institute ... another pathogen, ranavirus, may also contribute. , ... that ranavirus, which causes severe hemorrhage of internal ... populations of wood frogs if they are exposed ...
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... allergic diseases has risen dramatically in Western societies. One ... to microorganisms and have fewer infections than previous generations, ... study by researchers at Sahlgrenska Academy, University of Gothenburg, ... maturation of the immune system in relation to allergic ... of the Vstra Gtaland Region, half of them on ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... APS Healthcare, a leading provider of specialty healthcare solutions, ... Services to deliver a unified total population health management ... the State consolidated its service providers from three to ... population that APS has been serving for the past ...
... PROSPECT, Ill., May 5 The National Association of ... May 5, 2009, examining the flagrant lawlessness of Web ... why this ,wild west, of an electronic marketplace is ... dead and injured patients," the paper asserts. The "State ...
... May 5 Tim Wentworth, group president, employer accounts, Medco ... to address the Bank of America/Merrill Lynch 2009 Health Care ... at the Palace Hotel in New York City, will begin ... officer, is also scheduled to attend.The presentation may be heard ...
... in one Minnesota city , , TUESDAY, May 5 (HealthDay ... known, another learning disability -- the inability to write ... new study suggests. , So-called written-language disorder is a ... epidemiologist at the Mayo Clinic and lead author of ...
... with elevated albumin levels were more likely to get ... News) -- A higher-than-normal level of the protein albumin ... clots in the deep veins of the lungs and ... (VTEs) include deep vein thrombosis (DVT), a clotting in ...
... NIH and Robert Wood Johnson Foundation-Sponsored Study Focuses on ... 5 Nearly 75 percent of children ages 3-6 ... getting enough exercise. A focus group study of child ... several reasons children are not getting as much physical ...
Cached Medicine News:Health News:Ohio Selects APS Healthcare to Manage Unified Population Health Management Program for State Employees 2Health News:NABP Position Paper Calls for Action Against Proliferation of Rogue Internet Drug Outlets 2Health News:NABP Position Paper Calls for Action Against Proliferation of Rogue Internet Drug Outlets 3Health News:Medco to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:Writing Disorder May Be Common Among Kids 2Health News:Urine Test Predicts Vein Clot Risk 2Health News:Urine Test Predicts Vein Clot Risk 3Health News:ABCs and No Skinned Knees: Study Reveals Various Barriers to Physical Activity in Child Care 2Health News:ABCs and No Skinned Knees: Study Reveals Various Barriers to Physical Activity in Child Care 3
Preclude Dura Substitute is the only non-biological membrane designed to "seal" around suture holes. 0.3 mm as nominal thickness....
... synthetic absorbable implant for the bridging of Dura ... is pliable, regardless of being used dry or ... must be taken, while implanting, to ensure that ... is oriented towards the cortex or the spinal ...
... is a non-absorbable dura ... purified polyesterurethane. Its microporous ... of fibroblast, supporting tissue ... minimizes suture channels, resulting ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Medicine Products: